There is good news for cancer patients. The government has capped the price of exorbitantly priced trastuzumab , a life-saving drug used in breast cancer , at Rs 55,800 per injection, over 25% lower than the innovator Roche’s drug, Herceptin at Rs 75,000 per dose, among other oncology drugs .This is the first-ever instance of the drug pricing regulator, NPPA , fixing a ceiling on the biological breast cancer drug. The second significant medicine brought under price control is Pegylated Interferon used in cancer and hepatatis C treatment, with a ceiling price of Rs 14,515 per 100 mcg. The price revision follows key medicines used in cancer, Hepatitis B and C, being added in the National List of Essential Medicines earlier this year.The price changes communicated by the NPPA take place with immediate effect.In a decision notified on May 9, the NPPA has also fixed the retail price of 11 drugs, mainly anti-diabetic formulations. Industry body , IDMA said that it would seek some additional time to make the changes in the price packs. Copies of trastuzumab launched by Biocon and Zydus Cadila are also available in the market, but at a price much higher than the one capped by the government.